Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
LAB
Standard BioTools Inc.
CyTOF mass cytometry and Hyperion imaging systems are medical devices/biometrics platforms for advanced cellular analysis.
|
$588.27M |
$1.56
+1.30%
|
|
PACB
Pacific Biosciences of California, Inc.
PacBio directly manufactures diagnostic sequencing equipment (instruments) used in molecular diagnostics and research laboratories.
|
$582.72M |
$1.98
-3.19%
|
|
AVNS
Avanos Medical, Inc.
Avanos produces surgical equipment including radiofrequency ablation (RFA) systems and related devices used in procedures.
|
$573.07M |
$12.30
+0.33%
|
|
CRMD
CorMedix Inc.
DefenCath is an FDA-approved antimicrobial catheter-lock device marketed by CorMedix.
|
$569.57M |
$7.71
+2.66%
|
|
LXEO
Lexeo Therapeutics, Inc. Common Stock
Company is focused on AAV-based gene therapies (LX2006, LX2020) delivering therapeutic genes — direct Gene Therapy business.
|
$569.17M |
$10.55
+11.46%
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$568.45M |
$2.48
-0.60%
|
|
ABSI
Absci Corporation
Absci's core platform is an Antibody Discovery Platform combining AI design with high-throughput wet-lab validation (lab-in-the-loop) for de novo antibody generation.
|
$559.21M |
$3.87
+3.34%
|
|
VREX
Varex Imaging Corporation
Core Medical Imaging category representing imaging hardware and components used in medical devices.
|
$557.35M |
$13.49
+1.89%
|
|
RAPT
RAPT Therapeutics, Inc.
RAPT's pipeline includes oncology-focused assets under Biotech - Oncology (tivumecirnon) and broader oncology immunotherapy focus.
|
$556.00M |
$32.81
+5.16%
|
|
NPCE
NeuroPace, Inc.
Core product Neuromodulation device (RNS System) delivering brain-responsive, on-demand therapy for drug-resistant epilepsy.
|
$553.45M |
$16.57
-2.27%
|
|
VPG
Vishay Precision Group, Inc.
Medical infusion pump design win indicates participation in the Medical Devices & Biometrics market.
|
$553.34M |
$41.53
+2.85%
|
|
DNA
Ginkgo Bioworks Holdings, Inc.
Antibody Discovery Platform reflects the antibody-focused tools and services offered.
|
$547.01M |
$9.37
+3.37%
|
|
DSGN
Design Therapeutics, Inc.
Company develops small-molecule therapeutics (GeneTAC) targeting inherited nucleotide repeat disorders.
|
$534.74M |
$9.53
+3.81%
|
|
ORGO
Organogenesis Holdings Inc.
Core wound care device category covering Apligraf and Dermagraft, along with barrier products like PuraPly and FortiShield.
|
$534.07M |
$4.17
-1.07%
|
|
FULC
Fulcrum Therapeutics, Inc.
Fulcrum's lead asset pociredir is an oral small molecule therapeutic intended to induce HbF in SCD.
|
$532.80M |
$10.01
-0.99%
|
|
ZIMV
ZimVie Inc.
Dental Equipment—ZimVie directly designs and sells dental hardware used in clinics (implants, imaging, CAD/CAM, etc.).
|
$530.23M |
$18.99
|
|
PRME
Prime Medicine, Inc.
Directly develops gene editing therapeutics (Prime Editing) and the core therapeutic platform, i.e., gene therapy.
|
$530.22M |
$3.92
-0.13%
|
|
CYRX
Cryoport, Inc.
BioStorage/BioServices-like offerings place Cryoport in the realm of diagnostics/lab services and related bioservices for samples and storage.
|
$528.71M |
$10.54
+0.43%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is an oncology-focused therapeutic developed by SELLAS, targeting cancer antigens (WT1) and used as an immunotherapy.
|
$526.49M |
$4.09
-18.10%
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$515.37M |
$4.67
-6.87%
|
|
NUS
Nu Skin Enterprises, Inc.
The Prysm iO and related wellness devices involve medical/biometric device technology.
|
$511.31M |
$10.36
+0.34%
|
|
CRVS
Corvus Pharmaceuticals, Inc.
Lead pipeline includes oncology-focused therapies (soquelitinib) with activity in T-cell lymphomas, aligning with Oncology-focused biotech development.
|
$505.95M |
$6.79
-1.95%
|
|
EHAB
Enhabit, Inc.
EHAB's core operations are the provision of home health and hospice services directly to patients.
|
$505.38M |
$10.04
-1.52%
|
|
BIOA
BioAge Labs, Inc.
BioAge's lead program BGE-102 is an oral small-molecule therapeutic, and APJ agonists are being developed for obesity, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$502.98M |
$13.82
-0.72%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$494.70M |
$9.25
+2.21%
|
|
AUTL
Autolus Therapeutics plc
Core product: obe-cel CAR-T cell therapy (cell therapy) for rr B-ALL.
|
$481.72M |
$1.81
-4.97%
|
|
VSTM
Verastem, Inc.
Company is a oncology-focused biotech developing and commercializing cancer therapeutics.
|
$479.44M |
$7.91
+0.51%
|
|
SIGA
SIGA Technologies, Inc.
SIGA's core product is TPOXX, a small-molecule antiviral for orthopoxviruses, directly produced and marketed by the company.
|
$473.32M |
$6.68
-1.26%
|
|
LYEL
Lyell Immunopharma, Inc.
Lyell’s lead program LYL314 is a CAR-T cell therapy product targeting cancer (CD19/CD20 dual-target), the core business.
|
$471.64M |
$24.99
+2.84%
|
|
ZVRA
Zevra Therapeutics, Inc.
Zevra focuses on rare-disease therapeutics (NPC, UCD, VEDS) and related pipeline assets, core to rare disease biotech.
|
$466.48M |
$8.48
+2.05%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$465.98M |
$16.99
-0.06%
|
Showing page 17 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
